
|Videos|October 27, 2022
Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab
Author(s)Hetty E. Carraway, MD, Eytan M. Stein, MD
Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sigvotatug Vedotin Misses OS End Point in Phase 3 NSCLC Trial
2
ASCO 2026 Lung Cancer Abstracts: Clinical Practice Implications
3
FDA Grants Full Approval of Afami-Cel in Synovial Sarcoma, Expands Indication to 12 and Older
4
Zanzalintinib Plus Atezolizumab Misses OS End Point in Liver Metastasis–Free mCRC Subgroup
5










































